BioCentury | Oct 22, 2019
Emerging Company Profile

Intrepida: Tackling the innate immune system to treat cancer

With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3, which can modulate the innate immune response to inhibit tumor growth in pancreatic cancer....
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Interferon induced transmembrane protein 3 (IFITM3)

...Infectious disease INDICATION: Viral infection Cell culture studies suggest IFITM3 could help treat Zika viral infection...
...normal IFITM3 expression. Next steps include screening for small molecules that enhance IFITM3 levels. TARGET/MARKER/PATHWAY: Interferon induced transmembrane protein 3 (IFITM3)...
BioCentury | Jan 21, 2010
Distillery Therapeutics

Indication: Infectious disease

...IFITM3, that encoded factors required for viral infection. In vitro, overexpression of IFITM1, IFITM2 or IFITM3...
...Dengue fever infection. Next steps include developing transgenic animals to determine whether increasing levels of IFITM3...
Items per page:
1 - 3 of 3